Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Trims Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA lowered its position in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 60.0% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 185,891 shares of the medical research company's stock after selling 279,095 shares during the quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA's holdings in Edwards Lifesciences were worth $14,587,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Turtle Creek Wealth Advisors LLC acquired a new stake in Edwards Lifesciences in the fourth quarter worth $34,000. Operose Advisors LLC lifted its position in Edwards Lifesciences by 247.0% in the 3rd quarter. Operose Advisors LLC now owns 635 shares of the medical research company's stock valued at $44,000 after purchasing an additional 452 shares during the last quarter. SRS Capital Advisors Inc. boosted its stake in Edwards Lifesciences by 292.6% during the 3rd quarter. SRS Capital Advisors Inc. now owns 636 shares of the medical research company's stock valued at $44,000 after purchasing an additional 474 shares during the period. NBC Securities Inc. acquired a new position in Edwards Lifesciences during the 3rd quarter valued at about $52,000. Finally, ORG Partners LLC bought a new position in Edwards Lifesciences in the 3rd quarter worth about $66,000. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Stock Performance

Shares of EW stock traded up $1.02 during trading hours on Monday, reaching $86.96. 2,401,575 shares of the company's stock were exchanged, compared to its average volume of 3,846,708. The business has a fifty day moving average price of $90.15 and a 200-day moving average price of $78.52. The stock has a market capitalization of $52.34 billion, a P/E ratio of 37.81, a P/E/G ratio of 4.26 and a beta of 1.05. The company has a quick ratio of 2.40, a current ratio of 3.38 and a debt-to-equity ratio of 0.09. Edwards Lifesciences Co. has a fifty-two week low of $60.57 and a fifty-two week high of $96.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings data on Tuesday, February 6th. The medical research company reported $0.64 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.64. The business had revenue of $1.53 billion for the quarter, compared to analysts' expectations of $1.50 billion. Edwards Lifesciences had a return on equity of 23.56% and a net margin of 23.35%. Edwards Lifesciences's quarterly revenue was up 13.3% on a year-over-year basis. During the same period in the previous year, the business posted $0.64 earnings per share. Analysts predict that Edwards Lifesciences Co. will post 2.76 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Royal Bank of Canada lifted their price target on Edwards Lifesciences from $95.00 to $101.00 and gave the company an "outperform" rating in a research report on Monday, April 15th. Stifel Nicolaus raised their price objective on shares of Edwards Lifesciences from $70.00 to $83.00 and gave the company a "hold" rating in a research report on Wednesday, February 7th. StockNews.com downgraded shares of Edwards Lifesciences from a "buy" rating to a "hold" rating in a report on Wednesday, March 20th. Bank of America upgraded shares of Edwards Lifesciences from a "neutral" rating to a "buy" rating in a report on Thursday, March 7th. Finally, Wells Fargo & Company raised Edwards Lifesciences from an "equal weight" rating to an "overweight" rating and set a $94.00 price target on the stock in a report on Friday, February 2nd. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have issued a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $91.73.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, Director Michael A. Mussallem sold 29,350 shares of Edwards Lifesciences stock in a transaction on Monday, March 4th. The stock was sold at an average price of $86.67, for a total value of $2,543,764.50. Following the completion of the transaction, the director now owns 4,486 shares in the company, valued at approximately $388,801.62. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, VP Daniel J. Lippis sold 1,715 shares of the stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $90.98, for a total transaction of $156,030.70. Following the sale, the vice president now directly owns 17,213 shares of the company's stock, valued at $1,566,038.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Michael A. Mussallem sold 29,350 shares of the business's stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $86.67, for a total transaction of $2,543,764.50. Following the completion of the transaction, the director now owns 4,486 shares of the company's stock, valued at approximately $388,801.62. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 194,004 shares of company stock valued at $17,166,254. Corporate insiders own 1.27% of the company's stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.